Craig Collard serves as the Chief Executive Officer at Heron Therapeutics Inc., a position he has held since joining the company in January 2019. With a robust background in the biopharmaceutical industry, Collard has brought significant leadership and strategic vision to Heron Therapeutics. Prior to his role at Heron, he held several high-profile positions, including Chief Operating Officer at Esperion Therapeutics, where he played a pivotal role in the development and commercialization of new therapies. His career also includes a tenure at Baxter International, where he served as President of their BioScience business, overseeing global operations and driving substantial growth. Under Collard's leadership, Heron Therapeutics has focused on advancing its portfolio of innovative treatments, particularly in the areas of oncology and acute care. One of his notable achievements at Heron has been the successful commercialization of Zynrelef, a non-opioid pain management solution that has gained significant traction in the market. Collard's strategic initiatives have also included strengthening the company's pipeline through targeted research and development efforts, as well as forging key partnerships to enhance Heron's market position. His commitment to improving patient outcomes and his ability to navigate complex regulatory environments have been instrumental in steering the company towards sustained growth and success. In his role as CEO, Craig Collard continues to drive Heron Therapeutics forward by fostering a culture of innovation and excellence. His leadership style emphasizes collaboration and transparency, ensuring that the company remains agile and responsive to the evolving needs of the healthcare industry. Collard's vision for Heron is to become a leader in providing cutting-edge therapies that address unmet medical needs, and his strategic guidance is pivotal in realizing this goal. With a proven track record of transforming organizations and a deep understanding of the biopharmaceutical landscape, Collard is well-positioned to lead Heron Therapeutics into its next phase of growth and development.